Company: PBH
Filing Date: 2025-05-09
Form Type: 10-K
Source: 0001295947-25-000017
Chunk: 129

Company: Prestige Consumer Healthcare Inc.
Filing Date: 2025-05-09
Form: 10-K
Item: Item 8
Chunk 129
---
.  In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement).  We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not be material to our financial condition or results of operations.Lease CommitmentsSee Note 7 for a description of our operating and finance leases.Purchase CommitmentsWe have supply agreements for the manufacture of some of our products.  The following table shows the minimum amounts that we are committed to pay under these agreements:(In thousands) Year Ending March 31,Amount2026$3,927 20273,874 20283,508 20291,638 2030— Thereafter—  $12,947 

17.     Concentrations of Risk

Our revenues are concentrated in the area of OTC Healthcare.  We sell our products to mass merchandisers, drug, food, dollar, convenience and club stores and e-commerce channels.  During 2025, 2024 and 2023, approximately 37%, 38% and 39%, respectively, of our gross revenues were derived from our five top selling brands.  Two customers, Walmart and Amazon, accounted for more than 10% of our gross revenues during 2025. During 2025, 2024 and 2023, Walmart accounted for approximately 19%, 20% and 20%, respectively, of our gross revenues.  During 2025 and 2024, Amazon accounted for approximately 14% and 11%, respectively, of our gross revenues.  At March 31, 2025, approximately 18% of our accounts receivable were owed by Walmart and approximately 20% of our accounts receivable were owed by Amazon.    Our product distribution in the United States is managed by a third-party through one primary distribution center in Clayton, Indiana. We also operate a manufacturing facility in Lynchburg, Virginia, which manufactures certain of our Fleet, Monistat, Summer's Eve and Debrox products, representing approximately 15% of our gross revenues. We also operate a manufacturing facility in Victoria, Australia, which manufactures some of our Hydralyte and F